Drugmaker Viatris (VTRS.O) narrowly missed first-quarter revenue estimates on Thursday, hurt by weak sales for its older drugs such as cholesterol medication Lipitor and Norvasc for high blood pressure.
Net sales in its branded drugs unit, which makes up two-thirds of the company's total revenues, also fell 4.5% to $2.31 billion.

Pfizer (PFE.N) has agreed to pay $93 million to settle antitrust claims by wholesale drug distributors that accused it of conspiring with India's Ranbaxy Laboratories to delay sales of less expensive, generic versions of the cholesterol drug Lipitor.

Pfizer has again been sued over a deal it struck years ago that delayed generic competition to Lipitor, still the best-selling drug of all time. The lawsuit comes from national pharmacy chain CVS, which claims the deal cost it hundreds of millions of dollars.

December 4, 2006 proved to be a fateful day for Pfizer – the day when it announced that the highly touted cholesterol modifying drug, torcetrapib, was being dropped from development.